.Pharmacolibrary.Drugs.ATC.B.B01AB02

Information

Antithrombin III is a naturally occurring inhibitor of several coagulation enzymes, primarily thrombin and factor Xa. It is used therapeutically as a replacement therapy in patients with hereditary or acquired antithrombin deficiency, often to prevent thromboembolic events during high-risk procedures. Antithrombin III (human plasma-derived or recombinant) is approved and used clinically.

Pharmacokinetics

Pharmacokinetics in healthy adults and patients with hereditary antithrombin deficiency; administered as intravenous bolus or infusion.

References

1. Moffett, BS, et al., & Yee, DL (2017). Population pharmacokinetics of human antithrombin concentrate in paediatric patients. British journal of clinical pharmacology 83(11) 2450–2457. DOI:10.1111/bcp.13359 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28664670

2. Marzo, A, et al., & Parenti, M (2002). Pharmacokinetic behaviour of antithrombin III following intravenous infusion in healthy volunteers. Arzneimittel-Forschung 52(3) 187–193. DOI:10.1055/s-0031-1299878 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11963646

3. Völler, S, et al., & Hempel, G (2018). Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia. Cancer chemotherapy and pharmacology 81(2) 305–314. DOI:10.1007/s00280-017-3492-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29204688

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)